Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

INTRODUCTION: We report on the results of the German early access program (EAP) with the third-generation ALK- and ROS1-inhibitor lorlatinib. PATIENTS AND METHODS: Patients with documented treatment failure of all approved ALK/ROS1-specific therapies or with resistance mutations not covered by appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Nikolaj, Christopoulos, Petros, Kauffmann-Guerrero, Diego, Stratmann, Jan, Riedel, Richard, Schaefer, Monica, Alt, Jürgen, Gütz, Sylvia, Christoph, Daniel C., Laack, Eckart, Faehling, Martin, Fischer, Richard, Fenchel, Klaus, Haen, Sebastian, Heukamp, Lukas, Schulz, Christian, Griesinger, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876585/
https://www.ncbi.nlm.nih.gov/pubmed/33613692
http://dx.doi.org/10.1177/1758835920980558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876585/
https://www.ncbi.nlm.nih.gov/pubmed/33613692
http://dx.doi.org/10.1177/1758835920980558

Ejemplares similares